Immunotherapy and Paraneoplastic Neurological Syndromes
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Paraneoplastic Neurological Syndromes (PNS) are rare remote effects of cancer, not directly
attributed to mass lesions, metastases, infections, ischemia, coagulopathy, metabolic
disruptions or tumour treatment. Currently, PNS treatment is mostly limited to tumour
treatment. Because of an initial inflammatory stage early in the evolution of the PNS several
immunotherapy modalities have been tried. Intravenous human immunoglobulins could be expected
to provide a stabilization or even improvement of PNS, if administered early enough to
prevent permanent neuronal damage.